LYON, France, Nov. 7, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound for the treatment of prostate cancer, announced Ablatherm-HIFU achieved significant recognition at the annual World Congress of Endourology that concluded Saturday, November 3, in Cancun, Mexico. At the meeting, Ablatherm-HIFU was officially included within the "Robotic Alternatives" classification of localized prostate cancer treatments. This category includes robotic medical devices, basically represented by the widely known DaVinci robotic surgical device from Intuitive Surgical. The Ablatherm now joins the DaVinci as the sole HIFU technology in this classification.

EDAP was the only company presenting prostate cancer HIFU at the conference and participating in the official scientific program for Prostate Cancer. Ablatherm-HIFU is the only HIFU device for prostate cancer that is robotic. This allows for more precise treatment that is not operator-dependent, guarantying predictable outcomes for patients.

"The inclusion of Ablatherm in the Robotic Alternatives category by the WCE represents further acceptance of EDAP's technology as a standard of care for localized prostate cancer," said EDAP CEO Marc Oczachowski. "This designation represents EDAP's standalone clinical depth, significant user experience spanning more than 13,500 patients and more than 160 centers, and clear commitment to consistent therapeutic outcomes driven by clearly defined application protocols to ensure what is without any doubt the highest quality of HIFU care available to patients today."

Ablatherm users continued documenting the success of the device with two poster presentations from Munich centers, one from Regensburg, Germany, and one from Belgium. Ablatherm pioneer Pr. Christian Chaussy was recognized with a lifetime achievement award for his clinical efforts in bringing new developments and innovations to the urology community, among them the HIFU technology through the Ablatherm device for the treatment of prostate disease.

These successes follow recent news of EDAP's accelerating pace in Europe where Revenue Per Procedure growth has been approximately 40% as compared with the previous year and the company's recent announcement of $20 million raised to fund the company's U.S. clinical trial program where major centers are treating patients with the Ablatherm device intending to secure FDA approval.

Dr. John Rewcastle, EDAP's Medical Director, commented: "The WCE classification of Ablatherm-HIFU in the Robotic Alternatives category is significant for two reasons. First, it further substantiates the ever increasing acceptance of HIFU as a prostate cancer therapy. Second, the 'Ablatherm' specific nature of the categorization reinforces the fact that the vast majority of the world's HIFU data has been generated with the Ablatherm. The depth of clinical data available with the Ablatherm is unique in the HIFU realm and demonstrates that the procedure is a safe, effective and reproducible treatment for localized prostate cancer with durable cancer control."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is a treatment for patients with newly diagnosed localized prostate cancer or who have failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

To sign up for alerts please visit: http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A.    
         Blandine Confort 
         +33 4 78 26 40 46

         Magnolia Investor Relations     
         Matt Kreps                   
         469 362 5960